These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37866713)

  • 1. Pyrazolidinone-based peptidomimetic SARS-CoV-2 M
    Jelisejevs D; Bula AL; Kinena L
    Bioorg Med Chem Lett; 2023 Nov; 96():129530. PubMed ID: 37866713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
    Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J
    Eur J Med Chem; 2023 Nov; 259():115667. PubMed ID: 37482021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
    Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
    J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.
    Wang Q; Chen G; He J; Li J; Xiong M; Su H; Li M; Hu H; Xu Y
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of highly potent covalent SARS-CoV-2 3CL
    Zhang FM; Huang T; Wang F; Zhang GS; Liu D; Dai J; Zhang JW; Li QH; Lin GQ; Gao D; Zhao J; Tian P
    Eur J Med Chem; 2023 Nov; 260():115721. PubMed ID: 37598484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
    Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
    Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
    Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
    Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease.
    Ngo C; Fried W; Aliyari S; Feng J; Qin C; Zhang S; Yang H; Shanaa J; Feng P; Cheng G; Chen XS; Zhang C
    J Med Chem; 2023 Sep; 66(17):12237-12248. PubMed ID: 37595260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor.
    Hu X; Lin C; Xu Q; Zhou X; Zeng P; McCormick PJ; Jiang H; Li J; Zhang J
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114596. PubMed ID: 35839690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds.
    Zhu J; Zhang H; Lin Q; Lyu J; Lu L; Chen H; Zhang X; Zhang Y; Chen K
    Drug Des Devel Ther; 2022; 16():1067-1082. PubMed ID: 35450403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
    Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y
    J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease.
    Amblard F; LeCher JC; De R; Zhou S; Liu P; Goh SL; Tao S; Patel D; Downs-Bowen J; Zandi K; Zhang H; Chaudhry G; McBrayer T; Muczynski M; Al-Homoudi A; Engel J; Lan S; Sarafianos SG; Kovari LC; Schinazi RF
    Eur J Med Chem; 2024 Mar; 268():116263. PubMed ID: 38432056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of SARS-CoV-2 M
    Citarella A; Moi D; Pedrini M; Pérez-Peña H; Pieraccini S; Dimasi A; Stagno C; Micale N; Schirmeister T; Sibille G; Gribaudo G; Silvani A; Giannini C; Passarella D
    Org Biomol Chem; 2023 May; 21(18):3811-3824. PubMed ID: 37078164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
    Kneller DW; Li H; Phillips G; Weiss KL; Zhang Q; Arnould MA; Jonsson CB; Surendranathan S; Parvathareddy J; Blakeley MP; Coates L; Louis JM; Bonnesen PV; Kovalevsky A
    Nat Commun; 2022 Apr; 13(1):2268. PubMed ID: 35477935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fast and Effective Prediction of the Absolute Binding Free Energies of Covalent Inhibitors of SARS-CoV-2 Main Protease and 20S Proteasome.
    Zhou J; Saha A; Huang Z; Warshel A
    J Am Chem Soc; 2022 May; 144(17):7568-7572. PubMed ID: 35436404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.